Tamoxifen and 5-fluorouracil in breast cancer: modulation of cellular RNA.
Biochemical studies were undertaken with the human breast carcinoma cell line, 47-DN, to explore the mechanisms underlying cytotoxic synergy between tamoxifen (TAM) and the fluoropyrimidines, 5-fluorouracil (FUra) and 5-fluorouridine (FUrd). The influence of TAM pretreatment was measured on intracellular FUra accumulation, FUra nucleotide formation, and incorporation of fluoropyrimidines into cellular RNA. Unlike other modulators of FUra metabolism and toxicity. TAM decreased intracellular FUra accumulation and total RNA incorporation by 20 to 60%. Cells treated with TAM contained 10 to 20% less cellular RNA and showed reduced transcription and altered RNA turnover, independent of fluoropyrimidine treatment. Newly synthesized RNA from control and TAM-treated cells was fractionated by sucrose gradient centrifugation. The specific incorporation of FUrd (2 hr) was compared to that of FUra (6 hr) and labeled uridine incorporation into controls. Compared to its effect on uridine incorporation, TAM produced nearly twice as much FUra incorporation and 3 times as much FUra incorporation into 32 to 45S RNA. Since accumulation of this high-molecular-weight RNA has been associated with fluoropyrimidine toxicity and impaired ribosomal RNA processing, it is believed that TAM enriched the RNA-mediated toxicity of FUra and FUrd in this breast carcinoma cell line.
D001943:Breast Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D002460:Cell Line; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D006801:Humans; D007700:Kinetics; D012334:RNA, Neoplasm / Q000235:genetics*; D013629:Tamoxifen / Q000627:therapeutic use / Q000633:toxicity*; D014158:Transcription, Genetic / Q000187:drug effects*
D012334:RNA, Neoplasm; D013629:Tamoxifen; D005472:Fluorouracil